BIIB017 (peginterferon beta-1a)

Phase 3

Biogen Inc. (BIIB)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

BIIBPhase 3$33.1B

BIIB017 (peginterferon beta-1a) Phase 3 Est. Readout

BIIB017 (peginterferon beta-1a)• Multiple Sclerosis, Relapsing-Remitting152

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Multiple Sclerosis, Relapsing-Remitting

View Full Landscape

Drug Information

Target Indication

Multiple Sclerosis, Relapsing-Remitting

Clinical Trial

NCT03958877

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/18/2014

Plegridy

Treatment of relapsing remitting multiple sclerosis in adult patients.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

BIIB

Biogen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

MidazolamPhase 3

Relapsing-Remitting Multiple Sclerosis

SalanersenPhase 3

Muscular Atrophy, Spinal

AvonexPhase 3

Multiple Sclerosis

dimethyl fumaratePhase 3

Relapsing-Remitting Multiple Sclerosis

natalizumabPhase 3

Crohn's Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts